RxDoctor Payments Data

Joyce Gonzales, MD

Pulmonary Disease · Augusta, GANPI 1912120528

Payments from drug & device makers

$2,123in general payments, 2019–2025

Across 44 payments — averaging $48.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$679
  • Actelion Pharmaceuticals US, Inc.$274
  • Inari Medical, Inc.$172
  • Insmed, Inc.$151
  • AstraZeneca$135
  • Merck$127
  • plus $585 from 15 others

What the payments were for

  • Food & beverage$2,118100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,123 in reported general payments places this provider in the 30th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$28,638
Medicare patients
128
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan60$742,560
AdempasRiociguat46$636,686
Ambrisentan151$493,776
LetairisAmbrisentan29$380,476
WinrevairSotatercept-Csrk16$340,560
UptraviSelexipag14$313,295
OfevNintedanib Esylate23$216,695
Orenitram ErTreprostinil Diolamine39$198,337
AdcircaTadalafil12$84,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$77,144
Breo ElliptaFluticasone/Vilanterol99$39,489
Tadalafil65$23,999
Spiriva RespimatTiotropium Bromide21$15,881
Incruse ElliptaUmeclidinium Bromide26$11,701
EliquisApixaban11$6,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$274$1,055,85574 claims
MerckWinrevair$127$340,56016 claims
Boehringer IngelheimOfev, Spiriva Respimat$34$232,57644 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$20$128,335221 claims
United Therapeutics CorporationAdcirca$679$84,57112 claims
AstraZenecaSymbicort$135$4,58716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →